Mobia Medical posted second‑quarter Revenue of $13.5 million, a 102% jump from the same period a year earlier, driven by higher Vivistim system adoption. The surge lifts the company’s top‑line trajectory, suggesting stronger Demand that could underpin future Earnings growth despite a widened net loss.

Key Highlights

  • Revenue rose 102% YoY to $13.5 million, while gross Margin improved to 83.2%
  • Q2 revenue reached $13.5 million, a 102% increase from the same quarter a year earlier.
  • Gross margin improved slightly to 83.2% from 82.3% YoY, reflecting modest pricing power.
  • Operating expenses surged 83% to $29.2 million, driving an EPS loss of $0.88 versus the $0.66 consensus estimate.

Mobia Medical (NASDAQ: MOBI) reported second‑quarter revenue of $13.5 million, a 102% increase from the $6.7 million earned a year earlier, as Vivistim adoption accelerated across stroke‑recovery centers. Earnings Per Share came in at $‑0.88 versus a consensus estimate of $‑0.66, underscoring the cost pressures of rapid expansion. The strong top‑line lift positions Mobia to meet its ambitious full‑year revenue target while managing higher operating costs.

Revenue Doubles YoY

The quarter’s headline figure shows revenue of $13.5 million, more than double the $6.7 million recorded in the comparable period of 2025, delivering 102% growth. Gross Profit rose in tandem to $11.2 million, a 105% increase, while gross margin edged higher to 83.2% from 82.3% a year ago, indicating modest pricing power amid rising freight costs. Nonetheless, earnings per share missed expectations, posting a loss of $‑0.88 compared with the $‑0.66 consensus, a gap that highlights the impact of escalating expenses.

Investors should note that the surge in sales stems primarily from higher Vivistim system uptake, suggesting a growing addressable market for chronic stroke therapy. The earnings miss signals that revenue growth alone will not offset cost acceleration without further efficiency gains.

Financial Mechanics

Operating expenses exploded 83% to $29.2 million, up from $16.0 million a year prior, driven by personnel, commission, development, and general‑administrative outlays required to scale the commercial organization. The company’s cash pile sits at $177.1 million, bolstered by $134.0 million raised in a May IPO that converted redeemable preferred stock and convertible notes into common equity. The expanding expense base warns that profitability hinges on sustaining revenue momentum while trimming cost growth.

Market Context and Investor Implications

The market cap of $423 million reflects the premium investors place on the company’s innovative Vivistim paired VNS therapy, which targets a large unmet need among chronic stroke survivors. The strong revenue acceleration, coupled with a high gross margin, suggests that the firm’s core technology can command pricing resilience even as operating costs climb. However, the widening loss per share and elevated expense ratio imply that valuation multiples may be vulnerable to any slowdown in adoption rates.

Forward Outlook

Management will assess progress against this guidance in the upcoming third‑quarter earnings release, where performance against the revenue target will be a key metric for investors. The company’s cash runway and recent IPO proceeds provide a cushion to sustain growth initiatives, but execution risk remains as operating expenses continue to climb. The next Quarterly Report will reveal whether the revenue momentum can translate into narrowing losses and improved earnings per share, a decisive Factor for the stock’s trajectory.